Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

Bi-Cheng Wang; Bo-Ya Xiao; Guo-He Lin

doi:10.1186/s12885-022-09469-5

BMC Cancer (Mar 2022)

Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

Bi-Cheng Wang,
Bo-Ya Xiao,
Guo-He Lin

Affiliations

Bi-Cheng Wang: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Bo-Ya Xiao: Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Guo-He Lin: Department of Oncology, the Second Affiliated Hospital of Anhui Medical University

DOI: https://doi.org/10.1186/s12885-022-09469-5
Journal volume & issue: Vol. 22, no. 1
pp. 1 – 10

Abstract

Read online

Highlights 1. Nearly 44% of relapsed Ewing sarcoma patients achieved an ORR after IT treatment. 2. Relapsed Ewing sarcoma treated with IT had an over 66% DCR. 3. IT chemotherapy caused low incidences of neutropenia, thrombocytopenia, and diarrhea in treating relapsed Ewing sarcoma.

Published in BMC Cancer

ISSN: 1471-2407 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://bmccancer.biomedcentral.com

About the journal

Abstract

Keywords